Home » Stocks » ACOR

Acorda Therapeutics, Inc. (ACOR)

Stock Price: $0.707 USD 0.001 (0.16%)
Updated November 23, 10:58 AM EST - Market open

Stock Price Chart

Key Info

Market Cap 33.92M
Revenue (ttm) 165.30M
Net Income (ttm) 49.11M
Shares Out 47.96M
EPS (ttm) 1.02
PE Ratio 0.69
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 23
Last Price $0.707
Previous Close $0.706
Change ($) 0.001
Change (%) 0.16%
Day's Open 0.720
Day's Range 0.691 - 0.720
Day's Volume 624,581
52-Week Range 0.422 - 2.780

More Stats

Market Cap 33.92M
Enterprise Value 188.93M
Earnings Date (est) Feb 18, 2021
Ex-Dividend Date n/a
Shares Outstanding 47.96M
Float 47.12M
EPS (basic) 1.02
EPS (diluted) 1.02
FCF / Share -1.93
Dividend n/a
Dividend Yield n/a
Earnings Yield 144.23%
FCF Yield n/a
Payout Ratio n/a
Shares Short 7.24M
Short Ratio 0.90
Short % of Float 15.36%
Beta 0.94
PE Ratio 0.69
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.21
PB Ratio 0.11
Revenue 165.30M
Operating Income -89.56M
Net Income 49.11M
Free Cash Flow -91.97M
Net Cash -155.01M
Net Cash / Share -3.23
Gross Margin 95.31%
Operating Margin -54.18%
Profit Margin 29.70%
FCF Margin -55.64%
ROA -6.37%
ROE 16.51%
ROIC 17.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 1
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$2.33*
(229.47% upside)
Low
1.00
Current: $0.707
High
5.00
Target: 2.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue192471588520493401336306292191
Revenue Growth-59.19%-19.86%13.22%5.47%22.71%19.34%10.01%4.65%53%-
Gross Profit158374476411400321270248226155
Operating Income-39993.49-192-17.4845.3038.8230.3725.6035.04-8.42
Net Income-27333.68-223-34.6211.0617.6716.4415530.61-11.77
Shares Outstanding47.5147.0146.0045.2642.2341.1540.2139.4639.0038.36
Earnings Per Share-5.750.71-4.86-0.760.250.420.393.840.76-0.31
EPS Growth-----40.48%7.69%-89.84%405.26%--
Operating Cash Flow-12815197.1429.6538.4874.6539.2952.1266.34-19.22
Capital Expenditures-90.43-33.33-13.69-6.19-5.92-5.08-4.04-10.38-2.19-2.45
Free Cash Flow-21911783.4523.4632.5669.5735.2441.7464.14-21.66
Cash & Equivalents169446307159359309274234296240
Total Debt2503443353312932914.375.396.377.33
Net Cash / Debt-80.67103-27.64-17266.6417.80270229290233
Assets8001,3001,1981,3421,1111,065607565379342
Liabilities489688678678508525167179174191
Book Value311612520664603540440386205151
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Acorda Therapeutics, Inc.
Country United States
Employees 344
CEO Ronald Cohen

Stock Information

Ticker Symbol ACOR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ACOR
IPO Date February 10, 2006

Description

Acorda Therapeutics, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.